logo
logo

Clene Nanomedicine, Inc. Raises an Oversubscribed $42.5M Series D

Clene Nanomedicine, Inc. Raises an Oversubscribed $42.5M Series D

08/27/20, 5:38 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsalt lake city
Money raised
$42 million
Round Type
series d
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on the development of first-in-class nanocatalysts for the treatment of bioenergetic failure associated with neurodegenerative diseases, today announced the $42.5 million oversubscribed closing of its Series D equity financing. Proceeds from the financing will be used to advance Clene’s clinical pipeline—particularly the lead nanocatalyst, CNM-Au8—an orally administered therapeutic under investigation for the neurorepair of various neurodegenerative diseases including multiple sclerosis, Parkinson’s disease, and ALS, with one Phase 3 trial and four Phase 2 studies ongoing.

Company Info

Company
Clene
Location
salt lake city, utah, united states
Additional Info
Clene Nanomedicine, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit www.clene.com.